BioRestorative Therapies (BRTX) Total Non-Current Liabilities (2012 - 2025)

BioRestorative Therapies (BRTX) has 14 years of Total Non-Current Liabilities data on file, last reported at $1.1 million in Q2 2025.

• Quarterly Total Non-Current Liabilities rose 31.77% year-over-year to $1.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.1 million (up 31.77% YoY) and the FY2024 annual result came in at $1.2 million, up 15.44% from the prior year.
• Total Non-Current Liabilities rose to $1.1 million in Q2 2025, from $1.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.3 million in Q1 2024 to a low of -$10.0 million in Q4 2021.
• A 5-year average of -$192622.9 and a median of $1.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities slumped 275.67% — and 2022, when it jumped 106.05%.
• Tracing BRTX's Total Non-Current Liabilities over 5 years: stood at -$10.0 million in 2021, then jumped by 106.05% to $602619.0 in 2022, then soared by 76.46% to $1.1 million in 2023, then advanced by 15.44% to $1.2 million in 2024, then declined by 11.14% to $1.1 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $1.1 million (Q2 2025), $1.0 million (Q1 2025), and $1.2 million (Q4 2024), per Business Quant data.